← Oncology Approval Tracker

FDA DECISION ·

Darzalex Faspro

daratumumab + hyaluronidase-fihj · Janssen Biotech

FDA approvalNew formulationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with multiple myeloma: with bortezomib, melphalan and prednisone when newly diagnosed and transplant-ineligible; with lenalidomide and dexamethasone when newly diagnosed and transplant-ineligible or after at least one line; with bortezomib and dexamethasone after at least one line; or alone after at least three lines including a proteasome inhibitor and an immunomodulatory drug, or with double-refractory disease.

LAMPGEN ANALYSIS

Why it matters

Provided a subcutaneous alternative to intravenous daratumumab in several settings.

What research teams should watch

Separate route-specific orders and maintain observation and transfusion compatibility procedures.

PRIMARY RECORDS

Sources